Assessing bone strength in patients with metastatic cancer using CT scans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the fracture risk in patients with osteolytic bone metastases through quantitative CT (qCT) scans and numerical simulations. It focuses on patients with metastatic breast cancer and non-small cell lung cancer, utilizing routine imaging data to improve the assessment of bone integrity. The study seeks to enhance current methods, which are often empirical and lack sensitivity, by providing a more accurate evaluation of fracture risk. By integrating advanced imaging techniques, the study aims to optimize patient management and treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (\> 18 years of age).
* Patients who do not object to participating in the study. For patients participating to the biological collection: signature of the written informed consent..
* Patients with secondary tumor lesion(s) of mammary or pulmonary non-small cell, renal, bladder, thyroid or myeloma bone origin.
* Existence of a CT scan focused on the target lesion (or which will be performed as part of the care), performed within a time window of 30 days before and 20 days after inclusion, as part of the patient's usual bone management.
* Target location: upper end of the femur (1/3 proximal) and/or vertebrae. Several locations are possible for the same patient, provided that the inclusion criteria are met for each target.
* Size of target lesion: either diffuse permeative or \> 15 mm in size.
* Exposure to systemic bone therapy for 3 months or less (daily clodronate or denosumab, zoledronic acid, monthly pamidronate) is allowed
* Patients who received previous systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) are eligible.

Exclusion Criteria:

* Patients who have received targeted treatment at the target location either in the form of radiotherapy, surgery or interventional radiology (cementoplasty, cryotherapy, radiofrequency).
* Fractured pathological target bone.
* For the femur target, the patient must not have a hip prosthesis on either side (target or contralateral)
* Patients under trusteeship.

Where it's running

• Service de rhumatologie, CHU d'Angers
  Angers, France Recruiting
• Ch Annecy Genevois
  Annecy, France Recruiting
• Service de radiothérapie, Institut Jean-Perrin
  Clermont-Ferrand, France Recruiting
• Service de rhumatologie, CH Annemasse
  Contamine-sur-Arve, France Recruiting
• Service d'onco-rhumatologie, Centre Oscar Lombret
  Lille, France Recruiting
• Service de Radiothérapie, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian
  Lyon, France Recruiting

Study contacts

• Principal investigator: Cyrille CONFAVREUX, PR — Service de Rhumatologie
• Study coordinator: Cyrille CONFAVREUX, PR
• Email: cyrille.confavreux@chu-lyon.fr
• Phone: 4.78.86.12.31

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Personalized treatment after endocrine therapy failure in metastatic breast cancer

  The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07895160

• SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer

  This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.

  Recruiting Phase 2 Shenyang Sunshine Pharmaceutical Co., LTD. · Guangzhou, Guangdong · NCT07757230

• SMP-656 in HER2-positive advanced breast cancer after ADC therapy

  This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.

  Recruiting Phase 2 Chengdu SciMount Pharmatech Co., Ltd. · Hefei, Anhui and 14 other locations · NCT07726342

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.